Want to see IN:VALIANTLAB full AI Analyst Report?
VALIANTLAB Stock Chart & Stats
₹73.50
-₹2.57(-2.33%)
At close: 4:00 PM EST
₹73.50
-₹2.57(-2.33%)
Day’s Range― - ―
52-Week Range₹47.60 - ₹130.00
Previous CloseN/A
Volume41.92K
Average Volume (3M)43.43K
Market Cap
₹6.77B
Enterprise Value₹2.92K
Total Cash (Recent Filing)₹331.50M
Total Debt (Recent Filing)₹462.12M
Price to Earnings (P/E)41.8
Beta0.47
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding54,312,500
10 Day Avg. Volume12,604
30 Day Avg. Volume43,432
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.06
Price to Sales (P/S)1.39
P/FCF Ratio-6.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FY2026 Revenue ReboundFY2026 revenue rebounded 29.2% after two years of steep declines, indicating demand recovery for the API portfolio. If sustained, higher scale could improve manufacturing-cost absorption and rebuild earnings capacity, although current profitability remains weak.
Modest LeverageA sizable equity base relative to debt gives Valiant Laboratories a comparatively supported balance sheet and limits leverage pressure. This financial cushion can improve resilience and preserve flexibility to fund operations or capacity needs through the next several quarters.
API Supply Business ModelThe company serves a necessary position in the pharmaceutical supply chain by producing APIs used in finished medicines. Contracted orders and ongoing supply arrangements can support repeat demand and provide a foundation for durable customer relationships.
Bears Say
Persistent LossesThe shift from sustained earlier profits to losses in FY2025 and FY2026 shows that revenue recovery has not yet translated into dependable earnings. Continued losses could reduce internal funding capacity and weaken the company’s ability to reinvest or absorb operational setbacks.
Negative Cash GenerationNegative operating cash flow and deeply negative free cash flow indicate that the business is currently consuming cash rather than funding itself. If this pattern persists, greater reliance on external funding could constrain strategic flexibility and increase financial pressure.
Weak And Volatile Operating ProfitabilityOperating profit was near break-even in FY2026 despite the revenue rebound, while the preceding two-year decline highlights material earnings volatility. Thin operating profitability leaves limited protection against cost changes and makes durable margin recovery an important challenge.
Valiant Laboratories Ltd. News
VALIANTLAB FAQ
What was Valiant Laboratories Ltd.’s price range in the past 12 months?
Valiant Laboratories Ltd. lowest stock price was ₹47.60 and its highest was ₹130.00 in the past 12 months.
What is Valiant Laboratories Ltd.’s market cap?
Valiant Laboratories Ltd.’s market cap is ₹6.77B.
When is Valiant Laboratories Ltd.’s upcoming earnings report date?
Valiant Laboratories Ltd.’s upcoming earnings report date is Nov 17, 2026 which is in 56 days.
How were Valiant Laboratories Ltd.’s earnings last quarter?
Valiant Laboratories Ltd. released its earnings results on Aug 10, 2026. The company reported ₹3.886 earnings per share for the quarter.
Is Valiant Laboratories Ltd. overvalued?
According to Wall Street analysts Valiant Laboratories Ltd.’s price is currently Overvalued.
Does Valiant Laboratories Ltd. pay dividends?
Valiant Laboratories Ltd. does not currently pay dividends.
What is Valiant Laboratories Ltd.’s EPS estimate?
Valiant Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valiant Laboratories Ltd. have?
Valiant Laboratories Ltd. has 54,312,500 shares outstanding.
What happened to Valiant Laboratories Ltd.’s price movement after its last earnings report?
Valiant Laboratories Ltd. reported an EPS of ₹3.886 in its last earnings report. Following the earnings report the stock price went up 4.992%.
Which hedge fund is a major shareholder of Valiant Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:VALIANTLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valiant Laboratories Ltd.
Valiant Laboratories Limited, an India-based company, specializes in the production of active pharmaceutical ingredients (APIs) and bulk drugs, serving both domestic and international markets. Its primary product is paracetamol, manufactured in various grades that meet Indian, British, European, and United States pharmacopoeia standards. This crucial compound is utilized in treatments for common ailments such as headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. Beyond pharmaceuticals, the company also supplies specialty chemicals. Originally established in 1980 and headquartered in Mumbai, India, the firm rebranded as Valiant Laboratories Limited in August 2021, having previously operated under the name Bharat Chemicals. It functions as a subsidiary of Dhanvallabh Ventures LLP.
Technical Analysis
Albert David Ltd
―
Bafna Pharmaceuticals Limited
―
Medicamen Biotech Limited
―
Medico Remedies Ltd.
―
Zim Laboratories Ltd.
―